PSIL
AdvisorShares Psychedelics ETF
PSIL is actively managed to provide exposure to the emerging global psychedelics industry.
International
EQUITY
Active
MANAGEMENT STYLE
$ 24.1 M
ASSETS UNDER MGMT
99 bp
EXPENSES
Fund Basics
| Inception date | Sep 15, 2021 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| ATAI LIFE SCIENCES N.V. | 12.2 % |
| COMPASS PATHWAYS PLC ADR | 8.4 % |
| RELMADA THERAPEUTICS INC | 8.4 % |
| SUPERNUS PHARMACEUTICALS INC | 7.7 % |
| MIND MEDICINE INC ORDINARY SHARES | 7.5 % |
| CYBIN INC ORDINARY SHARES | 5.0 % |
| NRX PHARMACEUTICALS INC ORDINARY SHARES | 5.0 % |
| ALKERMES PLC | 4.7 % |
| GH RESEARCH PLC | 4.6 % |
| NEUROCRINE BIOSCIENCES INC | 4.5 % |
Constituent Breakdown
| Number of holdings | 30 |
| Herfindahl-Hirschman Index | 606 |
| Wgt avg mkt cap (mns) | $32,985 |
| Large cap (>$10bn) | 11.6% |
| Mid cap ($2-10bn) | 12.3% |
| Small cap (<$2bn) | 24.8% |
| Developed mkts. | 57.4% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 39.6 % |
 |
GERMANY | 12.2 % |
 |
IRELAND | 4.7 % |
 |
CANADA | 1.0 % |
Historical Performance
Standardized Performance (as of 03/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -1.6% | 45.3% | 6.5% | -3.3% | -- | -- | -- | -32.4% |
| Dividend Yield | 0.0% | 14.8% | 7.1% | 4.3% | -- | -- | -- | 2.3% |
| Total Returns | -1.6% | 60.0% | 13.6% | 1.0% | -- | -- | -- | -30.1% | Ann. Volatility | 42.9% | 43.0% | 82.9% | 71.1% | -- | -- | -- | 63.9% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.06 | 22% |
| MSCI EAFE | 1.02 | 18% |
| MSCI Emg Mkts | 0.90 | 18% |
Liquidity Measures
| Avg. volume (000) | 8 |
| ADV traded (mns) | $0 |
| Turnover | 0.6% |
| Avg. Bid/Ask (% of price) | 0.97% |
Technical Indicators
| 30d moving avg. (EMA) | $17.02 |
| Relative strength (RSI) | 53 |
| MACD/Signal | 0.18/0.04 |
| Bollinger Bands (Upper/Lower) | $18.02/$15.71 |
| Short interest (% of AUM) | 7.6% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PSIL |
Expenses vs. PSIL |
ALTAR Score™ vs. PSIL |
|---|---|---|---|---|
| IBRN | iShares Neuroscience and Healthcare ETF | 12.4% | -52 bp | +1.3% |
| MEDX | Horizon Kinetics Medical ETF | 11.0% | -14 bp | +2.8% |
Risk and Returns: PSIL vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 4/15/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-1.3%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 346 funds in the International Equity category with an average
ALTAR Score™ of 6.2% and a standard deviation
of 1.5%. PSIL's ALTAR Score™ is approximately -4.9 standard
deviations above the category average. This places PSIL in the 1st percentile
among funds in the category.
Sell-Side Consensus
$22.11
PRICE TARGET
+22.0%
UPSIDE
Bid/Ask Spreads
97 bp
AVG SPREAD
42 —
150 bp
RANGE